Outlook Therapeutics Inc
OTLK
Get informed when a big investor buys or sells
+ FollowMarket Cap$122.03M
Close$
$-0.11
116.2% downside
Current Fair Value
116.2% downsideOvervalued by 116.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $122.03 Million |
|---|---|
| Enterprise Value | $110.79 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.79 |
| Beta | 0.75 |
| Outstanding Shares | 25,476,438 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | -67771217.78% |
| Return on Invested Capital | 1256681106.34% |
Valuation & Multiples
| P/E Ratio | -0.35 |
|---|---|
| PEG | 0.35 |
| Price to Sales | 0.0 |
| Price to Book Ratio | 0.7 |
| Enterprise Value to Revenue | 0 |
| Enterprise Value to EBIT | 0 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | - |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 14, 2026
EPS Estimate
$-0.08
Average shareholder expectationRevenue Estimate
$966,667
Average shareholder expectationNext Earnings Call
Expected Date
December 18, 2026
EPS Estimate
$-0.06
Average shareholder expectationRevenue Estimate
$2.70 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.4689▼ 15.91% |
|---|---|
| Total Calls | 988,600▲ 300.57% |
| Total Puts | 463,600▲ 199.10% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 79.54%▲ 37.44% |
|---|---|
| Total Invested | $32.22M▲ 1360.12% |
| Investors Holding | 78▲ 19.00% |
ESG Score
No data
About Outlook Therapeutics Inc
8 employees
CEO: Lawrence Kenyon